X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ELDER PHARMA NATCO PHARMA/
ELDER PHARMA
 
P/E (TTM) x 23.1 -0.2 - View Chart
P/BV x 17.5 0.1 17,373.4% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 NATCO PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ELDER PHARMA
Jun-14
NATCO PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs877380 230.8%   
Low Rs424188 225.3%   
Sales per share (Unadj.) Rs223.4491.2 45.5%  
Earnings per share (Unadj.) Rs31.1-3.2 -976.5%  
Cash flow per share (Unadj.) Rs40.314.4 279.5%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.5376.5 58.3%  
Shares outstanding (eoy) m33.0720.54 161.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.90.6 503.3%   
Avg P/E ratio x20.9-89.3 -23.4%  
P/CF ratio (eoy) x16.119.7 81.9%  
Price / Book Value ratio x3.00.8 392.7%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5045,833 368.6%   
No. of employees `000NANA-   
Total wages/salary Rs m1,1282,179 51.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,38910,089 73.2%  
Other income Rs m167257 65.1%   
Total revenues Rs m7,55610,346 73.0%   
Gross profit Rs m1,793-792 -226.5%  
Depreciation Rs m304361 84.3%   
Interest Rs m3662,756 13.3%   
Profit before tax Rs m1,290-3,653 -35.3%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m309125 246.7%   
Profit after tax Rs m1,027-65 -1,572.1%  
Gross profit margin %24.3-7.8 -309.2%  
Effective tax rate %23.9-3.4 -698.6%   
Net profit margin %13.9-0.6 -2,146.7%  
BALANCE SHEET DATA
Current assets Rs m3,6819,240 39.8%   
Current liabilities Rs m3,1239,998 31.2%   
Net working cap to sales %7.6-7.5 -100.7%  
Current ratio x1.20.9 127.6%  
Inventory Days Days8946 193.2%  
Debtors Days Days5960 97.9%  
Net fixed assets Rs m7,68510,124 75.9%   
Share capital Rs m331206 160.8%   
"Free" reserves Rs m6,6705,582 119.5%   
Net worth Rs m7,2597,734 93.9%   
Long term debt Rs m9554,889 19.5%   
Total assets Rs m11,95722,882 52.3%  
Interest coverage x4.5-0.3 -1,390.2%   
Debt to equity ratio x0.10.6 20.8%  
Sales to assets ratio x0.60.4 140.2%   
Return on assets %11.711.8 99.1%  
Return on equity %14.2-0.8 -1,675.0%  
Return on capital %20.722.3 92.9%  
Exports to sales %39.43.0 1,295.0%   
Imports to sales %5.70.4 1,334.4%   
Exports (fob) Rs m2,908307 948.4%   
Imports (cif) Rs m42143 977.3%   
Fx inflow Rs m3,445307 1,123.7%   
Fx outflow Rs m703125 560.9%   
Net fx Rs m2,743181 1,512.7%   
CASH FLOW
From Operations Rs m1,44011,754 12.3%  
From Investments Rs m-1,089-561 194.3%  
From Financial Activity Rs m-353-6,762 5.2%  
Net Cashflow Rs m-14,432 -0.0%  

Share Holding

Indian Promoters % 52.0 39.6 131.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 7.5 104.5%  
FIIs % 16.6 16.8 99.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 36.1 72.0%  
Shareholders   25,395 16,479 154.1%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 22, 2018 03:11 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS